Shares of MannKind Co. (NASDAQ:MNKD) have earned a consensus rating of “Hold” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $1.89.
Several equities research analysts recently issued reports on MNKD shares. S&P Equity Research cut their price objective on MannKind from $3.49 to $2.77 in a report on Thursday, January 25th. HC Wainwright reiterated a “buy” rating on shares of MannKind in a report on Tuesday, October 24th. Maxim Group restated a “hold” rating on shares of MannKind in a report on Wednesday, November 1st. BidaskClub downgraded MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, Zacks Investment Research upgraded MannKind from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th.
MannKind (NASDAQ:MNKD) traded up $0.06 during mid-day trading on Monday, hitting $2.99. The company had a trading volume of 3,329,665 shares, compared to its average volume of 5,005,482. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28. The stock has a market cap of $343.47, a P/E ratio of -11.07 and a beta of 3.18. MannKind has a 52-week low of $0.67 and a 52-week high of $6.96.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Zeke Capital Advisors LLC purchased a new stake in MannKind during the 4th quarter worth about $306,000. Raymond James & Associates boosted its position in shares of MannKind by 54.6% during the 4th quarter. Raymond James & Associates now owns 156,554 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 55,266 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of MannKind by 1,083.3% during the 4th quarter. Two Sigma Advisers LP now owns 170,400 shares of the biopharmaceutical company’s stock worth $395,000 after acquiring an additional 156,000 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of MannKind by 14.7% during the 4th quarter. Geode Capital Management LLC now owns 551,568 shares of the biopharmaceutical company’s stock worth $1,279,000 after acquiring an additional 70,542 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of MannKind by 82.8% during the 4th quarter. BlackRock Inc. now owns 3,534,811 shares of the biopharmaceutical company’s stock worth $8,201,000 after acquiring an additional 1,600,802 shares in the last quarter. Institutional investors own 14.86% of the company’s stock.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.